UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States.
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
UFP Technologies, Inc. holds its Markdown at $299.95. Elevated stress, defensive posture warranted, held for 17 days.
As held on the ledger · 2026-08-27
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 17 days
Price at the screen
$299.95
Valuation
32.39 trailing · 25.26 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.06
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.58%
Below 33%
Interest-bearing debt is just 23.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
15.76%
Below 49%
Money owed to the company is 15.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 2.7% margin of safety to the base estimate.
Third-party analyst targets: 2 covering, consensus None. The average target sits +18% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Medical drapes maker priced beyond its steady growth
Every robotic surgery starts with a sterile drape that must fit perfectly and stay reliable under pressure. UFP Technologies builds those custom components plus protective packaging for medical devices across the United States. The business clears our ethical screen and delivers an 11 percent profit margin with 17 percent return on equity, yet it still fails to clear our bar.
At 20.7 times forward earnings the shares sit only modestly below our fair value of 290 dollars while revenue expands just 4 percent a year. Two analysts see a higher target, but the modest growth and unknown competitive edge leave no real margin of safety once normal business cycles are considered. We therefore pass.
Currency swings and single-industry concentration add further uncertainty, and any slowdown in elective procedures would hit volumes quickly. Low analyst coverage also means surprises travel further than the numbers suggest. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
UFPT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-15Markup$322.46+37.3%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 37.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (2 analysts) rates it none, with a mean price target of $324.
2026-07-18Markup$234.94+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (2 analysts) rates it none, with a mean price target of $324.
2026-07-03Markup$234.94+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$234.94Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
